Centre for the Commercialization of Antibiotics and Biologics and ImmunoBiochem partner for TNBC

The Centre for the Commercialization of Antibodies and Biologics (Toronto, Ontario) provided an undisclosed sum to ImmunoBiochem Corp. (Toronto, Ontario), which the biotech will use to develop IMB-212 which is in development to treat triple-negative breast cancer. ...